Measurement issues in using pharmacy records to calculate adherence to antiretroviral drugs

HIV Clinical Trials

Volumn 14, Issue 2, 2013, Pages 68-74

  Grimes, Deanna E ^a,b   Andrade, Roberto A ^c   Niemeyer, Chad R ^c   Grimes, Richard M ^b,d  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON   (United States)

^b Baylor UT Houston Center for AIDS Research   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

adherence; antiretroviral therapy; pharmacy records

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; AGED; ARTICLE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; PHARMACY; PRESCRIPTION; PRIORITY JOURNAL; VIRUS LOAD; ELECTRONIC MEDICAL RECORD; MIDDLE AGED;

ADULT; AGED; FEMALE; HUMANS; MALE; MEDICAL RECORDS SYSTEMS, COMPUTERIZED; MEDICATION ADHERENCE; MIDDLE AGED; PHARMACIES;

MLCS; MLOWN;

EID: 84878891624     PISSN: 15284336     EISSN: 19455771     Source Type: Journal    
DOI: 10.1310/hct1402-68     Document Type: Article

References (26)

1. Berg KM, Arnsten JH. Practical and conceptual challenges in measuring antiretroviral adherence. J Acquir Immune Defic Syndr. 2006;43:S79-S87.
2. Paterson DL, Potoski B, Capitano B. Measurement of adherence to antiretroviral medications. J Acquir Immune Defic Syndr. 2002;31:S103-S106.
3. Kitahata MM, Reed S F, Dillingham PW, et al. Pharmacy based assessment of adherence to HAART predicts virologic and immunologic treatment response and clinical progression to AIDs and death. Int J STD AIDS. 2004;15(12):803-810.
4. Saberia P, Caswell N, Amodio-Grotonc M, Alpert P. Pharmacy-refill measure of adherence to efavirenz can predict maintenance of HIV viral suppression. AIDS Care. 2008;20(6):741-745.
5. Grossberg R, Zhang Y, Gross R. A time-to-prescription-refill measure of antiretroviral adherence predicted changes in viral load in HIV. J Clin Epidemiol. 2004; 57:1107-1110.
6. Wood E, Montaner JS, Yip B, et al. Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users. CMAJ. 2003;169:656-661.
7. Townsend ML, Jackson GL, Smith R, Wilson KH. Association between pharmacy medication refill-based adherence rates and CD4 count and viral-load responses: a retrospective analysis in treatment-experienced adults with HIV. Clin Ther. 2007;29:711-716.
8. Inciardi J F, Leeds AL. Assessing the utility of a community pharmacy refill record as a measure of adherence and viral load response in patients infected with human immunodeficiency virus. Pharmacotherapy. 2005;25: 790-796.
9. Cambiano V, Lampe FC, Rodger AJ, et al. Use of a prescription-based measure of antiretroviral therapy adherence to predict viral rebound in HIV-infected individuals with viral suppression. HIV Med. 2010;11: 216-224.
10. Fairley CK, Permana A, Read TR. Long-term utility of measuring adherence by self-report compared with pharmacy record in a routine clinic setting. HIV Med. 2005;6:366-369.
11. Low-Beer S, Yip B, O'Shaughnessy MV, Hogg RS, Montaner JS. Adherence to triple therapy and viral load response. J Acquir Immune Defic Syndr. 2000;23:360-361.
12. Wood E, Hogg RS, Yip B, et al. The impact of adherence on CD4 cell count responses among HIV-infected patients. J Acquir Immune Defic Syndr. 2004;35:261-268.
13. McMahon JH, Jordan MR, Kelley K, et al. Pharmacy adherence measures to assess adherence to antiretroviral therapy: review of the literature and implications for treatment monitoring. Clin Infect Dis. 2011;52(4):493-506.
14. de Boer IM, Prins JM, Sprangers MAG, Nieuwkerk PT. Using different calculations of pharmacy refill adherence to predict virological failure among HIV-infected patients. J Acquir Immune Defic Syndr. 2010;55(5):635-640.
15. Fischer MA, Stedman MR, Lii J, et al. Primary medication non-adherence: analysis of 195, 930 electronic prescriptions. J Gen Intern Med. 2010;25(4):284-290.
16. McNabb JC, Ross JW, Abriola K, Turley C, Nightingale CH, Nicolau D P. Adherence to highly active antiretroviral therapy predicts virologic outcome at an inner-city human immunodeficiency virus clinic. Clin Infect Dis. 2001;33:700-705.
17. Bisson G P, Gross Bellamy S, et al. Pharmacy refill adherence compared with CD4 count changes for monitoring HIV-infected adults on antiretroviral therapy. PLOS Med. 2008;5(5):778-788.
18. Bisson G P, Rowh A, Weinstein R, Gaolathe T, Frank I, Gross R. Antiretroviral failure despite high levels of adherence: discordant adherence-response relationship in Botswana. J Acquir Immune Defic Syndr. 2008;49:107-110.
19. Nellen J F, Nieuwkerk PT, Burger DM, Wibaut M, Gras LA, Prins JM. Which method of adherence measurement is most suitable for daily use to predict virological failure among immigrant and non-immigrant HIV-1 infected patients? AIDS Care. 2009;21:842-850.
20. Grimes RM, Grimes DE. Patient readiness to adhere to HAART. J Int Assoc Phys AIDS Care. 2009;8(6):364-366.
21. Gardner EM, Burman WJ, Maravi ME, Davidson AJ. Selective drug taking during combination antiretroviral therapy in an unselected clinic population. J Acquir Immune Defic Syndr. 2005;40:294-300.
22. Maher K, Klimas N, Fletcher MA, et al. Disease progression, adherence, and response to protease inhibitor therapy for HIV infection in an urban Veterans Affairs Medical Center. J Acquir Immune Defic Syndr. 1999;22:358-363.
23. Lima VD, Harrigan R, Bangsberg DR, et al. The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time. J Acquir Immune Defic Syndr. 2009;50:529-536.
24. Martin M, Del Cacho E, Codina C, et al. Relationship between adherence level, type of the antiretrovi-ral regimen, and plasma HIV type 1 RNA viral load: a prospective cohort study. AIDS Res Hum Retrovirus. 2008;24(10):1263- 1268.
25. Harrigan PR, Hogg RS, Dong WW, et al. Predictors of HIV drug resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis. 2005;191:339-347.
26. Gross R, Yip B, Lo Re V, et al. A simple, dynamic measure of antiretroviral therapy adherence predicts failure to maintain HIV-1 suppression. J Infect Dis. 2006;194:1108-1114.